Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults

NCT06205056 is registered in ClinicalTrials.gov with U.S. Army Medical Research and Development Command as lead sponsor.

NCT NCT06205056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06205056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults
Lead sponsor
U.S. Army Medical Research and Development Command
Phase
Phase 1
Overall status
Recruiting
Start date
January 30, 2024
Completion date
June 30, 2026
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus